Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TG Therapeutics Q4 2023 Adj EPS $(0.09) Beats $(0.10) Estimate, Sales $43.97M Beat $40.06M Estimate

Author: Benzinga Newsdesk | February 28, 2024 08:04am
TG Therapeutics (NASDAQ:TGTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. The company reported quarterly sales of $43.97 million which beat the analyst consensus estimate of $40.06 million by 9.75 percent. This is a 54.86K percent increase over sales of $80.00 thousand the same period last year.

Posted In: TGTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist